Fluctuations in anti-factor Xa levels with therapeutic enoxaparin anticoagulation in pregnancy

Journal of Perinatology

Volumn 30, Issue 4, 2010, Pages 253-257

  Friedrich, E ^a,b   Hameed, A B ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LONG BEACH MEMORIAL MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Enoxaparin; Factor Xa activity; Pregnancy

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ABSENCE OF SIDE EFFECTS; ADULT; ANTICOAGULANT THERAPY; ANTITHROMBIN III DEFICIENCY; ARTICLE; BLEEDING; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG TREATMENT FAILURE; FEMALE; HIGH RISK PATIENT; HUMAN; LEG THROMBOSIS; LUNG EMBOLISM; MORNING DOSAGE; MULTICENTER STUDY; OBESITY; PREGNANCY; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; SPONTANEOUS ABORTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; THROMBOSIS PREVENTION;

ADULT; CROSS-SECTIONAL STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; ENOXAPARIN; FACTOR XA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, SUBCUTANEOUS; PILOT PROJECTS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOPHILIA; YOUNG ADULT;

EID: 77950519729     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2009.164     Document Type: Article

References (25)

1. Rutherford SE, Phelan JP. Thromboembolic disease in pregnancy. Clin Perinatol 1986; 13: 719-739.
2. Curtis SL, Trinder J, Stuart AG. Acute thrombosis of a prosthetic mitral valve in pregnancy in spite of adjusted-dose low-molecular-weight heparin and aspirin. J Heart Valve Dis 2008; 17: 133-134.
3. Descarries LM, Leduc L, Khairy P, Mercier LA. Low-molecular-weight heparin in pregnant women with prosthetic heart valves. J Heart Valve Dis 2006; 15: 679-685.
4. James AH, Brancazio LR, Gehrig TR, Wang A, Ortel TL. Low-molecular-weight heparin for thromboprophylaxis in pregnant women with mechanical heart valves. J Matern Fetal Neonatal Med 2006; 19: 543-549. (Pubitemid 44373606)
5. Oran B, Lee-Parritz A, Ansell J. Low molecular weight heparin for the prophylaxis of thromboembolism in women with prosthetic mechanical heart valves during pregnancy. Thromb Haemost 2004; 92: 747-751. (Pubitemid 39386701)
6. Lepercq J, Conard J, Borel-Derlon A, Darmon JY, Boudignat O, Francoual C et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG 2001; 108: 1134-1140. (Pubitemid 33052475)
7. Greer I, Hunt BJ. Low molecular weight heparin in pregnancy: current issues. Br J Haematol 2005; 128: 593-601. (Pubitemid 40343227)
8. Ellison J, Walker ID, Greer IA. Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy. BJOG 2000; 107: 1116-1121.
9. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000; 160: 191-196. (Pubitemid 30054338)
10. Ginsberg JS, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 1998; 114: 524S-530S. (Pubitemid 28535779)
11. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 844S-886S. (Pubitemid 351892978)
12. Rowan JA, McCowan LM, Raudkivi PJ, North RA. Enoxaparin treatment in women with mechanical heart valves during pregnancy. Am J Obstet Gynecol 2001; 185: 633-637.
13. Casele HL, Laifer SA. Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium. J Matern Fetal Med 2000; 9: 122-125.
14. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-698. (Pubitemid 27375477)
15. Forestier F, Daffos F, Rainaut M, Toulemonde F. Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy. Thromb Haemost 1987; 57: 234. (Pubitemid 18044751)
16. Omri A, Delaloye JF, Andersen H, Bachmann F. Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy. Thromb Haemost 1989; 61: 55-56. (Pubitemid 19092668)
17. ACOG Committee Opinion. Safety of Lovenox in pregnancy. Number 276, October 2002. Committee on Obstetric Practice. Int J Gynaecol Obstet 2002; 79: 299-300.
18. Casele HL, Laifer SA, Woelkers DA, Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999; 181: 1113-1117.
19. Lebaudy C, Hulot JS, Amoura Z, Costedoat-Chalumeau N, Serreau R, Ankri A et al. Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy. Clin Pharmacol Ther 2008; 84: 370-377.
20. Jacobsen AF, Qvigstad E, Sandset PM. Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy. BJOG 2003; 110: 139-144. (Pubitemid 36263109)
21. Sephton V, Farquharson RG, Topping J, Quenby SM, Cowan C, Back DJ et al. A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. Obstet Gynecol 2003; 101: 1307-1311. (Pubitemid 36694360)
22. Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol 2004; 191: 1024-1029.
23. Abildgaard U, Gjestvang FT, Lossius P, Hodne E. Low molecular heparin in a pregnant women with heart valve prosthesis. Tidsskr Nor Laegeforen 1999; 119: 4319-4320.
24. Fox NS, Laughon SK, Bender SD, Saltzman DH, Rebarber A. Antifactor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis. Obstet Gynecol 2008; 112: 884-889.
25. Sanderink GJ, LeLiboux A, Jariwala N, Harding N, Ozoux ML, Shoukla U et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 2002; 72: 308-318.